CDK4/6 inhibitor-related interstitial lung disease in breast cancer: a single-center case series and literature-based patient-level review. (PubMed, J Thorac Dis) - Oct 14, 2026 - "Thirty patients had received palbociclib, 22 had received abemaciclib, and eight had received ribociclib. Because its presentation is nonspecific, evaluation should focus on high-resolution CT (HRCT) assessment, exclusion of infection, tumor progression and radiation-related lung injury, and severity-based decisions regarding drug interruption or discontinuation. BALF is most useful when infection remains a major competing diagnosis."
Journal • Acute Respiratory Distress Syndrome • Breast Cancer • Cough • Immunology • Infectious Disease • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor
|
|
Chunyu Liu; Fang Wang; Ran Li; Wentao Ni; Xinyu Fu; Zhancheng Gao
|